Stockscreener 앱 받기
195.22
3.28%
6.20
시간 외 거래:
194.90
-0.32
-0.16%
Abbvie Inc 주식(ABBV)의 최신 뉴스
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today - AOL.com
AbbVie reports encouraging data from Upadacitinib trial for alopecia areata - MSN
AbbVie's Q2 2025 Earnings Call: Unpacking Contradictions in Skyrizi Growth, Inventory Strategies, and Market Dynamics - AInvest
AbbVie Shines in Earnings Call with Strong Growth - The Globe and Mail
Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more - Seeking Alpha
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer - The Globe and Mail
AbbVie Reports Strong Q2 2025 Financial Results - The Globe and Mail
AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume - AInvest
Why AbbVie Stock Flew Higher on Friday - Nasdaq
Major pharma company takes on Oregon 340B drug law - The Business Journals
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Why Is AbbVie Stock Gaining Friday?AbbVie (NYSE:ABBV) - Benzinga
Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining - Benzinga
Why AbbVie (ABBV) Stock Is Up Today - Yahoo Finance
AbbVie’s New Study on CLL Treatment: A Potential Game Changer? - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail
AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Call Transcript - MSN
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential - TipRanks
AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... - Yahoo.co
Stock Analysis | Abbvie OutlookA Mixed Technical Picture Amid Divergent Analyst Ratings - AInvest
AbbVie's Stock Dips 0.15% as Trading Volume Surges 108.9% to Rank 50th in Market Activity Behind Strong Q2 Earnings - AInvest
M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics - TipRanks
AbbVie Stock Pops After Earnings Beat and Guidance Raised - MSN
Why AbbVie Stock Slumped Today - Yahoo Finance
Market Today: Meta and Microsoft Lead AI Surge, AbbVie Eyes Acquisition - GuruFocus
AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength - insights.citeline.com
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A - BioPharma Dive
Research Alert: CFRA Retains Buy Opinion On Shares Of Abbvie Inc. - 富途牛牛
CoreWeave, Arm Holdings, AbbVie: Trending Tickers - Yahoo Finance
AbbVie Earnings: Continued Impressive Demand for Skyrizi, Neuroscience Portfolio Support Growth - Morningstar
AbbVie: Q2 Earnings Snapshot - The Washington Post
Trump demands largest pharma companies slash US drug prices - Yahoo Finance
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow - MarketBeat
Earnings call transcript: AbbVie Q2 2025 sees stock surge on earnings beat - Investing.com Canada
AbbVie sees no outsized tariff exposure, boosts profit forecast - Reuters
AbbVie Lifts Forecasts As Immunology Drugs Drive Growth - Finimize
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks - Seeking Alpha
Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook - Yahoo Finance
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View - Yahoo Finance
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer? - The Globe and Mail
AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier - Yahoo Finance
AbbVie Stock Pops After Earnings. What’s Driving Shares Higher. - Barron's
AbbVie Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AbbVie raises guidance as key drugs and pipeline deals boost growth - Crain's Chicago Business
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AbbVie 2nd-quarter beats expectations - The Pharma Letter
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg
AbbVie lifts profit forecast on strong demand for newer immunology drugs - Reuters
Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts - The Wall Street Journal
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates - Yahoo.co
Is Now the Time to Buy AbbVie Ahead of a Pivotal Transition? - AInvest
AbbVie raises full-year earnings guidance amid acquisition drive - Yahoo Finance
AbbVie lifts guidance despite slump in Humira sales - MSN
AbbVie in charts: Revenues from Humira -58%, Skyrizi +62%, Rinvoq +42% Y/Y - MSN
AbbVie earnings beat by $0.01, revenue topped estimates By Investing.com - Investing.com South Africa
AbbVie stock gains as company posts Q2 beat (ABBV:NYSE) - Seeking Alpha
1.57%
자본화:
|
볼륨(24시간):